Date: 2012-11-13
Type of information: Licensing agreement
Compound: APO010
Company: Topotarget (Denmark) Oncology Venture (Denmark)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: APO010 is an anti-cancer drug comprising multimerised Fas ligand, which utilizes Topotarget’s proprietary Mega ligand technology (a non-core component of Topotarget’s IP assets). APO010 targets Fas receptors on the surface of cancer cells and induces cell death via apoptosis. APO010 has shown activity in otherwise drug-resistant cells.
Disease:
Details: As Topotarget continues to focus its operations on the company’s lead candidate belinostat, the company has entered into an exclusive license agreement with Oncology Venture ApS granting Oncology Venture global rights to the further clinical development of APO010.
Under the agreement, Oncology Venture will license all rights specific to APO010 which are covered by Topotarget’s issued and pending patents in Europe, the US, Canada, Japan, Australia, South Korea, and other territories. The agreement also grants Oncology Venture the right to sub-license. No details of the terms of the agreement were disclosed.
Financial terms:
Latest news:
